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A comparative study of the levels of netilmicin in bronchial secretions after inter-
mittent and during continuous intravenous injections was performed. During the
first 2 h, the areas under the drug concentration curves in the bolus injection
experiment were greater in serum and in bronchial secretions (206 and 150%
respectively) than those associated with the continuous infusion (P<0i001);
however, during the 8 h experimental period, the areas under the curves were
similar in serum and bronchial secretions with the two modes of administration.
The percentages of penetration of netilmicin from the blood to the bronchial
lumen were also similar with the two modes of administration (19%). After intra-
muscular administration of amikacin (75 and 125 mg/kg twice daily), the peak
bronchial secretion levels of the drug were 44 and 10-1 mg/1 respectively and the
trough levels about 1 mg/1. During continuous iv injection of amikacin
(7-12 mg/kg/8 h), the drug level in the bronchial secretions was only 20 mg/1 and
the percentage of penetration was 14*9%; adequate anXi-Pseudomonas activity in
bronchial secretions was rarely achieved. It is therefore suggested that intermittent
injections of aminoglycosides can result in at least transitory higher bronchial
secretion levels than continuous injection: the intermittent schedule of antibiotic
administration could therefore be recommended in the treatment of broncho-
pulmonary infections since it has been suggested that the concentration of
antibiotic in bronchial secretions could be important in the outcome of these
infections.
Introduction
With respect to the optimal antibiotic regimen for bronchopulmonary infections, it
has been suggested that the concentrations of the antibiotic in bronchial secretions
might be of critical importance in the therapeutic outcome of these infections
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(Stewart et al., 1974; Maesen et al., 1976; Klastersky et al., 1979). The bioactive
levels of aminoglycosides in bronchial secretions after systemic administration are
relatively low when compared to the minimum inhibitory concentration of most
Gram-negative bacilli. This could be due mainly to two factors. On one hand, the
penetration of the aminoglycosides through the blood/bronchus barrier appears in
most studies to be relatively poor, the ratios between the peak bronchial and serum
levels are in the range of 10 to 30% (Pennington & Reynolds, 1973; Pennington &
Reynolds, 1975; McCrae, Raeburn & Hanson, 1976; Bergogne-Berezin, Even &
Berthelot, 1978). On the other hand, a partial bioinactivation of these antibiotics
occurs in purulent sputum: we have shown that the inactivation of netilmicin by
sputum may be correlated with the degree of purulence of the secretions (Thys &
Klastersky, 1980a).
Thus it is relevant to study the kinetics of aminoglycosides in bronchial secretions
to determine the optimal mode of systemic administration of the antibiotics which
could ensure high and sustained bronchial levels, exceeding the MIC of the offending
pathogen. In the first part of the present work the penetration of netilmicin into the
bronchial secretions after intermittent and during continuous intravenous adminis-
tration was studied. Bronchial levels of amikacin after intramuscular injection and
during continuous infusion were also compared.
Material and methods
The patients were hospitalized in the Neurosurgical Unit of the Institut Jules Bordet.
They presented, at the time of the study, with tracheobronchitis, i.e. purulent
bronchial secretions without clinical or radiological signs of parenchymal involve-
ment; in some patients it was associated with bronchopneumonia. All the patients
had endotracheal intubation or a tracheostomy and the bronchial secretions, not
mixed with saliva, were collected through these routes. The absence of spontaneous
antibacterial activity in serum and in bronchial secretions was controlled before
each experiment. The samples of serum and bronchial secretions were stored at
—20*C until assayed. The assays of netilmicin and amikacin were performed as
described by Bennett et al. (1966), using Bacillus subtilis as the test organism. Each
assay was made in triplicate. To prepare the reference curves, human serum was
used for the serum assays and undiluted supernatant of pooled bronchial secretions
obtained by centrifugation (14,000 rpm during 1 h) for bronchial secretions assays.
As far as these latter assays were concerned, we employed the centrifuged
supernatant of the bronchial secretions specimens.
Serum and bronchial secretions levels of netilmicin after intermittent and during
continuous iv injection
Ten patients were observed in a cross-over study, receiving netilmicin by inter-
mittent and continuous intravenous administration on two consecutive days. The
daily dose was 7-5 mg/kg. For intermittent administration, 25 mg/kg (dissolved in
9 ml of 5% dextrose in water) was injected over a 2 min period, as a direct bolus
injection, three times during a 24 h period. In the other experiment, the same
amount of netilmicin (7-5 mg/kg) was dissolved in 1000 ml of 5% dextrose in water
and was given as a continuous intravenous infusion using an automated infusion
device (Automated Infusion Unit, Decca, London) to control strictly the rate of
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administration. The samples of the serum and bronchial secretions to be studied
were obtained between the sixteenth and twenty-fourth hour, that is during the last
8 h, which were considered as a steady-state period. Blood and bronchial secretions
samples were obtained just before and at various intervals after bolus injections:
10 min, 30 min, 1 h, 2 h, 4 h, 6 h and 8 h. During the 8 h period of the continuous
infusion, samples were taken at 0,2 h, 4 h, 6 h and 8 h.
Serum and bronchial secretions levels of amikacin after intermittent and during
continuous iv injection
In a first group of six patients, 7-5 and 125 mg/kg were injected intramuscularly
twice daily during two consecutive days. Serum and bronchial secretions samples
were obtained just before and at 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 12 h after the
injection. Serum and bronchial secretions samples were obtained during the last 12 h
of the experiment which were considered to represent a steady-state period.
The second group of six patients received a loading dose of 4 mg/kg of amikacin
after which 7-12 mg/kg of the drug were continuously infused during 8 h. Two
samples of serum were obtained at 2-h intervals during the last 4 h of the injection.
The inhibitory and bactericidal activity in serum and supernatant of bronchial
secretions was measured against ten strains of Pseudomonas aeruginosa (MIC for
amikacin 1-5-6 mg/1).
Results
Serum and bronchial secretions levels of netilmicin after intermittent and during
continuous iv injection
Levels in serum. After the bolus injection, the mean peak serum level was
12-4 ± 09 mg/1 (mean ± s.E.)at 10 min (Thys, Mouawad & KJastersky, 1979); after
4 and 8 h, the mean serum levels were 2-5 ± 05 and 10 ± 0 3 mg/1 respectively, as
shown in Figure 1. During the continuous infusion, the mean serum level remained
stable at 3 3 ± 0 3 mg/1. During the first 2 h of the experiment, the area under the
curve associated with the bolus infusion was nearly double (206%) that associated
with the continuous injection (P<0001, Student's Mest). However, during the total
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Figure 1. Serum netilmicin levels after bolus injection (•) and during continuous infusion (A).
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duration of the experiment (8 h) the areas under the curve with the two modes of
administration were similar (975%).
Levels in bronchial secretions. In the bolus injection experiment, the mean peak of
netilmicin in bronchial secretions obtained at 30min was 1-1 ± 02 mg/1 as
indicated in Figure 2; 4 h and 8 h later, the mean bronchial secretions levels were
0 5 ± 01 and 04 ±0*1 mg/1 respectively. The mean level during the continuous
infusion experiment was 0 6 ± 0-1 mg/1. As in the serum, the area under the curve
in the bolus injection experiments during the first 2 h was considerably greater
(150%) than that of the continuous infusion (P< 0001, Student's /-test) Figure 2;
however, there was no difference between the areas under the curves during the 8-h
period with the two modes of intravenous administration (969%).
Penetration of netilmicin across the blood bronchus barrier. The percentage of
penetration (ratio of the areas under the curves in bronchial secretions and in serum
x 100) of netilmicin across the blood/bronchus barrier were calculated with the two
modes of administration: this percentage calculated during the continuous adminis-
tration is identical to that observed during the 8 h of the bolus experiment (193%
and 192%, respectively). However, the penetration during the first 2 h of the bolus
experiment is smaller than that observed during the same period of the continuous
infusion (14-4 vs. 19-7%)(/><005).
Serum and bronchial secretions levels of amikacin after intermittent and during
continuous iv injections
Repeated im injections of amikacin. After the im injection of 75 mg/kg of
amikacin, the mean peak serum level was 20'7 ± 27 mg/1 (mean ± s.E.) (Figure 3)
(Thys & Klastersky, 19806); 6 and 12 h later, the mean serum levels were 46 ± 0 9
and 18 ± 08 mg/1 respectively. After the injection of 125 mg/kg, the mean
peak serum level was 36-2 ± 5-7 mg/1, and 6 and 12 h later, the corresponding
serum levels were 15-3 ± 47 and 47 ± 24 mg/1 respectively. As far as the
amikacin levels in the bronchial secretions are concerned, the mean peak level was
4 4 ± 0 7 mg/1 after the injection of 75 mg/kg (Figure 3); 6 and 12 h later, the
bronchial levels were 41 ± 10 and 0 9 ± 0 3 mg/1 respectively. After the injection
of 125 mg/kg, the mean peak bronchial level was 10" 1 ± 2 2 mg/1; the levels
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Figure 2. Bronchial secretions netilmicin levels after bolus injection (•)and during continuous infusion
(A).
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Figure 3. Bronchial secretions and serum amikacin levels after im administration. Serum: 7'5 mg/kg
(• • ) ; 12-5 mg/kg (O O). Bronchial secretions: 75 mg/kg (• • ) ; 125 mg/kg (O O).
observed 6 and 12 h later were 70 ± 21 and 11 ± 0-5 mg/1 respectively. With
these two dosages, the percentages of penetration of amikacin into the bronchial
lumen were similar (420 and 362% respectively).
Continuous injection of amikacin. The mean serum amikacin level was
128 ± 14 mg/1 (mean ± s.E.) (Table I). The serum level of the drug was constant as
indicated by little variations between samples taken at 2 h intervals. The mean
bronchial secretions level was 20 ± 0"4 mg/1. There was a correlation between
serum and bronchial secretions amikacin levels (r = 077, P<005). The percentage
of penetration of the drug was 149%. Only one patient out of six had adequate
antibacterial activity in bronchial secretions (1/8, corresponding to an amikacin
bronchial secretion level of 4 mg/1). The five other patients had no satisfactory
antipseudomonas activity and had lower amikacin levels in the bronchial secretions
in spite of adequate serum levels of the drug and adequate serum bactericidal activity
(Mombellie/a/., 1982).
Discussion
Clinical experience indicates that the outcome of bronchial pulmonary infection
could be related, among other factors, to the level of antimicrobial activity which is
obtained in the bronchial secretions. Maesen et al. (1976), treated acute
exacerbations of chronic bronchitis with increasing doses of bacampicillin: in their
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Table I. Antibiotic concentration and anti-Pseudomonas activity in serum and bronchial
secretions during the continuous infusion of amikacin
Amikacin levels (mg/1)
Serum
Patient Single
number values at
2h
intervals
Mean
Bronchial
secretions
Bronchial
penetration
of amikacin
Bactericidal titre
against Ps. aeruginosa
(median values)
Serum Bronchialsecretions
1
2
3
4
5
6
Mean ± S.E.
8-2
140
140
10-5
13
18
84
130
140
88
15
15
83
13-5
140
9-65
14
17-5
1-3
1-3
1-5
1-4
2-3
40
15-7
96
107
14-5
164
22-8
:4
:8
:8
:8
:4
1 :2
1 :2
1 :2
1 :2
1 :2
1 :8
12-8 ± 1-4 20 ±0-4 14-9 ± 19
study, the clinical and microbiological success of the treatment was related to the
levels of ampicillin in the bronchial secretions. In a group of patients with acute
bronchitis or pneumonia treated with amoxycillin, Stewart et al. (1974) showed a
more favourable clinical outcome in the patients with a high sputum level of the
drug than those with a low one. More recently, Klastersky et al. (1979) treated two
groups of 20 tracheostomized patients with Gram-negative bronchopneumonia;
sisomicin or a placebo was administered endotracheally to these patients and, in
addition, all of them received systematically a combination of sisomicin and
carbenicillin. A favourable clinical response was more frequent in the group of
patients who received sisomicin endotracheally than in the group who received the
placebo (77 vs 45%) (Table II). The bronchial sisomicin level, 1 h after the
endotracheal instillation, was more than 1050 mg/1 in the sisomicin treated group
and only 045 mg/1 in the placebo group; the bactericidal activity of the bronchial
secretions was 1/256 or undetectable in the two groups, respectively. This last study
suggests a relationship between the clinical outcome of Gram-negative pulmonary
Table II. Treatment of Gram-negative bronchopneumonia with endotracheal sisomicin (with
sisomicin and carbenicillin iv)
Placebo Sisomicin
No. patients No. success No. patients No. success
Total number of patients 20 9(45%r 18 14(77%)*
Bronchial
secretions Serum
Bronchial
secretions Serum
Levels of sisomicin (mg/1)
(mean ± S.E.)
Bactericidal activity
045 ± 0 1 1 104 ± 0 2 5 1051 ± 2715 118 ± 0 2 8
0 1/8 1/256 1/8
•P<0-05.
Serum levels tissue penetration 35
infections, the bronchial level of the aminoglycoside and the bactericidal activity
within the bronchial secretions. Thus, the bronchial level of the antibiotic and the
resulting bactericidal activity are satisfactory criteria to evaluate the potential
effectiveness of a mode of administration of antibiotics for bronchopulmonary
infection.
The basic problem of the respective effectiveness of intermittent or continuous
administration of antibiotic is still unsolved; elsewhere in this issue, Barza reviews
personal data and other information from the literature on this subject. A short
comment about the work of Kozak et al. (1977) who compared bolus or prolonged
infusion as determinants of the degree and the rate of penetration of gentamicin into
intraperitoneally implanted capsules in rabbits is relevant. Their protocol was
relatively similar to our study of the bronchial penetration of netilmicin with bolus
or continuous injection. They injected 1*7 mg/kg of gentamicin as a rapid bolus
injection or as a slow intravenous injection. During the first 2 h of the experiment
the authors noted that the mean level of gentamicin in the intraperitoneal capsule
was slightly but significantly higher after the bolus injection than after the prolonged
infusion, but later the level became similar with the two modes of administration.
During the first 6 h the areas under the curves for serum and capsule fluid,
gentamicin levels obtained by rapid infusion were a little greater than those obtained
by slow injection. These data are in accordance with our study on the bronchial
penetration of netilmicin.
During the first 2 h the areas under the curves of netilmicin levels in bronchial
secretions resulting from bolus injection were significantly greater than those
following continuous infusion. The total areas under the curves corresponding to the
complete (8 h) experiment were, however, identical with the two modes of
administration. Similar conclusions were reached when areas under the curves in
serum were studied. Thus, in the work of Kozak et al. (1977), as in ours, during the
first 2 h of the experiment the amount of the antibiotic after the bolus injection at the
site of the potential infection (intraperitoneal capsule or bronchial secretions) was
significantly greater than with a continuous infusion. But over the total duration of
the experiments the amount of antibiotic, at the sites studied, were almost identical
with both modes of administration.
A basis of antibiotic therapy is to assure at the site of infection a drug level higher
than the minimum inhibitory concentration of the pathogen. If one considers the
sensitivity of most Enterobacteriacae and Ps. aeruginosa to aminoglycosides and the
bronchial levels of these drugs after bolus or during continuous intravenous
injection, it becomes clear that only the bolus injection is able to achieve, in the
bronchial secretions, levels of antibiotics which are adequate to inhibit most strains.
For netilmicin for example, administration of continuous infusion resulted in our
experiment in levels in bronchial secretions that were subinhibitory for most
pathogenic organisms responsible for bronchial infection in tracheostomized
patients in our hospital. On the contrary, repeated bolus injections resulted in higher
levels of netilmicin within the bronchial secretions that exceeded the MIC of most
pathogens. As far as our experiments with repeated intramuscular injection and
continuous infusion of amikacin were concerned the conclusions were similar
repeated injection resulted in higher bronchial levels of the drug which were
inhibitory for most pathogens, than continuous infusion of similar doses, which
resulted in irregular and lower levels and inconstant antibactericidal effects.
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It is therefore suggested that in order to obtain therapeutic levels of aminoglyco-
sides within the bronchial secretions intermittent administration of high doses of
aminoglycosides might be more effective than continuous infusion. Nevertheless,
even the bronchial levels of antibiotics that result from bolus injections were not
much higher than the inhibitory concentration for most pathogens. Since the
concentration of antibiotics in the bronchial secretion might be important in the
treatment of bronchopulmonary infection, endotracheal administration of amino-
glycoside, in order to obtain high and sustained levels of antibiotics as well as
an effective antibactericidal effect, might be indicated as an adjunct for the therapy
of severe Gram-negative bacillary bronchopulmonary infections (Klastersky et al.,
1979).
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